TY - JOUR
T1 - Frontal edema due to mesotherapy for androgenetic alopecia
T2 - A case series
AU - Melo, Daniel Fernandes
AU - Saceda-Corralo, David
AU - Tosti, Antonella
AU - Weffort, Flavia
AU - Carla Jorge, Machado
AU - de Barros, Claudia Carreira
AU - de Melo Carvalho, Raquel
AU - Starace, Michela
N1 - Publisher Copyright:
© 2021 Wiley Periodicals LLC.
PY - 2022/2
Y1 - 2022/2
N2 - Androgenetic alopecia (AGA) is the most common form of non-cicatricial alopecia in both genders. Currently approved drugs for the treatment of AGA include topical minoxidil in women and topical minoxidil and oral finasteride in men. Other routes of administration of approved drugs have been proposed to enhance therapeutic results for AGA, including intradermal injections, known as mesotherapy. Mesotherapy—or intradermotherapy—is a non-surgical procedure, consisting of multiple intradermal injections of pharmacological substances diluted in small doses. Although minimally invasive, mesotherapy may be related to mild side effects like burning, erythema and headaches, as a few reports indicate. Among the most serious adverse events, subcutaneous necrosis, scalp abscesses, and angioedema have been described. This multicenter retrospective, descriptive study aims to report 14 cases of frontal edema resulting from mesotherapy for AGA treatment. In our patients, the edema mostly arose in the first two sessions and lasted between 1 and 4 days, with a favorable outcome after a local cold compress. In all our cases of edema, lidocaine was the anesthetic used. Minoxidil and dutasteride might also play a role as causative agents. To the best of our knowledge, this is the largest case series focused on frontal edema after mesotherapy for AGA and gives clinicians helpful information for when performing this technique. Dermatologists should already consider and be conscious of this possible mesotherapy side effect, as it can be remarkably disruptive to affected patients.
AB - Androgenetic alopecia (AGA) is the most common form of non-cicatricial alopecia in both genders. Currently approved drugs for the treatment of AGA include topical minoxidil in women and topical minoxidil and oral finasteride in men. Other routes of administration of approved drugs have been proposed to enhance therapeutic results for AGA, including intradermal injections, known as mesotherapy. Mesotherapy—or intradermotherapy—is a non-surgical procedure, consisting of multiple intradermal injections of pharmacological substances diluted in small doses. Although minimally invasive, mesotherapy may be related to mild side effects like burning, erythema and headaches, as a few reports indicate. Among the most serious adverse events, subcutaneous necrosis, scalp abscesses, and angioedema have been described. This multicenter retrospective, descriptive study aims to report 14 cases of frontal edema resulting from mesotherapy for AGA treatment. In our patients, the edema mostly arose in the first two sessions and lasted between 1 and 4 days, with a favorable outcome after a local cold compress. In all our cases of edema, lidocaine was the anesthetic used. Minoxidil and dutasteride might also play a role as causative agents. To the best of our knowledge, this is the largest case series focused on frontal edema after mesotherapy for AGA and gives clinicians helpful information for when performing this technique. Dermatologists should already consider and be conscious of this possible mesotherapy side effect, as it can be remarkably disruptive to affected patients.
UR - http://www.scopus.com/inward/record.url?scp=85120936478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120936478&partnerID=8YFLogxK
U2 - 10.1111/dth.15247
DO - 10.1111/dth.15247
M3 - Article
C2 - 34877759
AN - SCOPUS:85120936478
VL - 35
JO - Dermatologic Therapy
JF - Dermatologic Therapy
SN - 1396-0296
IS - 2
M1 - e15247
ER -